# CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance

> **NCT07643493** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **David Dornbos** · enrollment: 80 (estimated)

## Conditions studied

- Tissue Plasminogen Activator
- Intraventricular Brain Hemorrhage

## Interventions

- **DRUG:** Tissue Plasminogen Activator (tPA)
- **PROCEDURE:** Isotonic solution

## Key facts

- **NCT ID:** NCT07643493
- **Lead sponsor:** David Dornbos
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-07-31
- **Primary completion:** 2028-05-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643493, "CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*